LXRX – Lexicon Pharmaceuticals Inc.
LXRX
$1.76Name : Lexicon Pharmaceuticals, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $745,677,888.00
EPSttm : -0.14
Lexicon Pharmaceuticals, Inc.
$1.76
LXRX — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
12.76
Margin Of Safety %
Put/Call OI Ratio
0.06
EPS Next Q Diff
-0.01
EPS Last/This Y
-0.04
EPS This/Next Y
-0.03
Price
1.72
Target Price
3.36
Analyst Recom
1.8
Performance Q
46.15
Upside
-206.4%
Beta
1.05
Ticker: LXRX
19 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-17 | LXRX | 1.625 | 0.05 | 0.05 | 37501 |
| 2026-03-18 | LXRX | 1.565 | 0.05 | 0.01 | 37584 |
| 2026-03-19 | LXRX | 1.615 | 0.05 | 0.01 | 37613 |
| 2026-03-20 | LXRX | 1.56 | 0.05 | 0.04 | 37628 |
| 2026-03-23 | LXRX | 1.63 | 0.04 | 0.09 | 31518 |
| 2026-03-24 | LXRX | 1.715 | 0.04 | 0.71 | 32534 |
| 2026-03-25 | LXRX | 1.685 | 0.04 | 0.01 | 32473 |
| 2026-03-26 | LXRX | 1.625 | 0.04 | 0.01 | 32480 |
| 2026-03-27 | LXRX | 1.645 | 0.04 | 0.00 | 32394 |
| 2026-03-30 | LXRX | 1.515 | 0.04 | 2.54 | 32706 |
| 2026-03-31 | LXRX | 1.56 | 0.06 | 0.00 | 33505 |
| 2026-04-01 | LXRX | 1.645 | 0.06 | 0.03 | 34603 |
| 2026-04-02 | LXRX | 1.59 | 0.06 | 0.00 | 34633 |
| 2026-04-06 | LXRX | 1.59 | 0.06 | 0.33 | 34740 |
| 2026-04-07 | LXRX | 1.605 | 0.06 | 0.00 | 34766 |
| 2026-04-08 | LXRX | 1.675 | 0.06 | 0.04 | 34758 |
| 2026-04-09 | LXRX | 1.775 | 0.06 | 0.20 | 34668 |
| 2026-04-10 | LXRX | 1.715 | 0.06 | 0.00 | 34786 |
| 2026-04-13 | LXRX | 1.715 | 0.06 | 0.00 | 34792 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
19 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-17 | LXRX | 1.62 | 50.0 | -30.5 | -0.18 |
| 2026-03-18 | LXRX | 1.57 | 50.0 | -27.2 | -0.18 |
| 2026-03-19 | LXRX | 1.62 | 50.0 | -32.0 | -0.18 |
| 2026-03-20 | LXRX | 1.56 | 50.0 | -27.0 | -0.18 |
| 2026-03-23 | LXRX | 1.63 | 50.0 | -33.0 | -0.18 |
| 2026-03-24 | LXRX | 1.72 | 50.0 | -33.7 | -0.18 |
| 2026-03-25 | LXRX | 1.68 | 50.0 | -28.2 | -0.18 |
| 2026-03-26 | LXRX | 1.62 | 50.0 | -27.1 | -0.18 |
| 2026-03-27 | LXRX | 1.64 | 50.0 | -30.2 | -0.18 |
| 2026-03-30 | LXRX | 1.51 | 50.0 | -24.0 | -0.18 |
| 2026-03-31 | LXRX | 1.56 | 50.0 | -32.3 | -0.18 |
| 2026-04-01 | LXRX | 1.64 | 50.0 | -33.6 | -0.18 |
| 2026-04-02 | LXRX | 1.59 | 50.0 | -27.5 | -0.18 |
| 2026-04-06 | LXRX | 1.59 | 50.0 | -30.2 | -0.18 |
| 2026-04-07 | LXRX | 1.61 | 50.0 | -30.7 | -0.18 |
| 2026-04-08 | LXRX | 1.67 | 50.0 | -33.0 | -0.18 |
| 2026-04-09 | LXRX | 1.78 | 50.0 | -34.7 | -0.18 |
| 2026-04-10 | LXRX | 1.72 | 50.0 | -27.9 | -0.18 |
| 2026-04-13 | LXRX | 1.72 | 50.0 | -29.5 | -0.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
19 items
«
‹
Current Page1 of 1
›
»
19 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-03-17 | LXRX | 0.85 | -29.70 | 12.87 |
| 2026-03-18 | LXRX | 0.85 | -29.70 | 12.87 |
| 2026-03-19 | LXRX | 0.85 | -29.70 | 12.87 |
| 2026-03-20 | LXRX | 0.85 | -29.70 | 12.87 |
| 2026-03-23 | LXRX | 0.85 | -29.70 | 12.87 |
| 2026-03-24 | LXRX | 0.85 | -29.70 | 12.87 |
| 2026-03-25 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-03-26 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-03-27 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-03-30 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-03-31 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-01 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-02 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-06 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-07 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-08 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-09 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-10 | LXRX | 0.85 | -29.70 | 12.62 |
| 2026-04-13 | LXRX | 0.85 | -29.70 | 12.76 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
19 items
«
‹
Current Page1 of 1
›
»
Last Quarter Act. EPS
-0.04
Avg. EPS Est. Current Quarter
-0.04
Avg. EPS Est. Next Quarter
-0.06
Insider Transactions
0.85
Institutional Transactions
-29.7
Beta
1.05
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
45
Growth Score
36
Sentiment Score
98
Actual DrawDown %
72.9
Max Drawdown 5-Year %
-95.2
Target Price
3.36
P/E
Forward P/E
PEG
P/S
14.55
P/B
5.78
P/Free Cash Flow
EPS
-0.14
Average EPS Est. Cur. Y
-0.18
EPS Next Y. (Est.)
-0.21
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-101.08
Relative Volume
0.28
Return on Equity vs Sector %
-74.1
Return on Equity vs Industry %
-57.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.07
EBIT Estimation
-29.5
◆
LXRX
Healthcare
$1.71
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
8/20
Pullback
14/25
Volume
11/15
Valuation
8/20
TP/AR
3/10
Options
8/10
RSI
57
Range 1M
67.1%
Sup Dist
1.9%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
9/25
Growth
10/30
Estimates
3/20
Inst/Vol
4/15
Options
8/10
EPS Yr
-26.5%
EPS NY
-16.4%
52W%
91.5%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+96.5% upside
Quality
7/30
Valuation
16/30
Growth
7/25
Stability
4/10
LT Trend
4/5
Upside
+96.5%
Quality
45
Click a card to see score breakdown
Full Analysis →
Sector: Healthcare
Industry: Biotechnology
Employees: 81
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
LXRX
Latest News
—
Caricamento notizie per LXRX…
stock quote shares LXRX – Lexicon Pharmaceuticals Inc. Stock Price stock today
news today LXRX – Lexicon Pharmaceuticals Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch LXRX – Lexicon Pharmaceuticals Inc. yahoo finance google finance
stock history LXRX – Lexicon Pharmaceuticals Inc. invest stock market
stock prices LXRX premarket after hours
ticker LXRX fair value insiders trading